Servier hit by bone drug safety issues as Mediator continues to make waves
This article was originally published in Scrip
The French company Servier, already staggering under the weight of the Mediator affair, is again under fire, this time over the safety profile of its osteoporosis drug, Protelos (strontium ranelate). A French committee is examining the pharmacovigilance data on the product to see whether its risk-benefit profile needs to change, and Servier's pharmacovigilance systems are also under the spotlight.
You may also be interested in...
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.